Evidence map›Paper›PMID 29455687›Full record

ArticlePsychological medicine2018

Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia.

Emilio Fernandez-Egea, Yulia Worbe, Miguel Bernardo, Trevor W Robbins

Abstract read
In one paragraph

Article in Psychological medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2019
    Article
  17. Article
  18. Review
  19. Article
  20. Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatmentJournal of psychiatry & neuroscience : JPN · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emilio Fernandez-EgeaClozapine Clinic, Cambridgeshire and Peterborough NHS Foundation Trust,Cambridge,UK.
Yulia WorbeSorbonne Université,75005 Paris,France;Department of Physiology,Neurophysiology Unit,Hospital Saint-Antoine,Paris,France;Institute du Cerveau et de Moelle Epigniere,Paris,France.
Miguel BernardoCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM),Barcelona,Spain.
Trevor W RobbinsBehavioural and Clinical Neuroscience Institute, University of Cambridge,Cambridge,UK.

Funding

Medical Research Council G00001354Medical Research Council G0001354Medical Research Council G1000183Wellcome TrustWellcome Trust 104631/Z/14/Z
6 · The paper itself

Abstract

backgroundObsessive-compulsive disorder (OCD) is common in clozapine-treated patients although the actual prevalence, phenomenology and risk factors remain unclear. The aim of the present study was to address the three aforementioned questions.

methodsThe electronic records of a large cohort of clozapine-medicated schizophrenia patients routinely screened for OCD were used. The Obsessive Compulsive Inventory Revised version (OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined.

resultsOCD prevalence was 47%, higher in patients on poly-pharmacy than on monotherapy (64% vs 31%; p = 0.001). Two OCI-R factors had significantly higher scores and distinct risk factors: checking behaviour (mean = 5.1; SD = 3.6) correlated with length of clozapine treatment (r = 0.21; p = 0.026), and obsessing factor (mean = 4.8; SD = 3.6) correlated with psychosis severity (r = 0.59; p = 0.001). These factors along with total OCI-R, did not correlate with either clozapine dose or plasma levels, after correcting for psychosis severity.

conclusionsScreening for OCD in clozapine patients, and probably in those treated with structurally similar drugs with potent antiserotoninergic properties, should be widely adopted by clinicians. Further research is needed to understand the pathophysiology underlying repetitive behavior onset in clozapine-treated patients.

Indexed as

AdultAntipsychotic AgentsClozapineCohort StudiesComorbidityCross-Sectional StudiesFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPolypharmacyPrevalenceRisk FactorsSchizophreniaUnited KingdomAntipsychotic AgentsClozapineAntipsychoticsclozapinehabit formationobsessive compulsive disorder.schizophrenia

Identifiers

PMID29455687
PMCPMC6236440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.